Dr. Hiroto Bando

President, Japan at Minaris Advanced Therapeutics

Speaker

Hiroto joined Minaris in 2020 and led the business through the sale from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004), to Altaris, LLC in 2024. Prior to Minaris, Hiroto was at Takeda Pharmaceuticals Co. Ltd (NYSE: TAK) and Fujifilm Holdings Corporation (TYO: 4901) where he held various roles such as Global Head of Cell Manufacturing Strategy, and Director of Strategic Product Planning. Hiroto holds a PhD in Pharmaceutical Science from Kyoto University, an MBA from Kenichi Ohmae Graduate School and a post doctorate in Pharmaceutical Sciences from the University of Texas.